Skip to main content
OpenTrials
Completed

NCT Number: NCT03435185

Greater Occipital and Supraorbital Nerve Blockade in Migraine Patients

The investigators aimed to evaluate the efficacy of greater occipital nerve and supraorbital nerve blockade with local anesthetics for the preventive treatment of migraine without aura.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Migraine Disorders Brain Diseases Central Nervous System Diseases Headache Headache Disorders Headache Disorders, Primary Nervous System Diseases Neurologic Manifestations Pain Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

A mixture of 1 ml 2% lidocaine and 0.9% 1 ml saline was injected bilaterally to GON and SON in the blockade patients. Placebo patients received 2 ml 0.9% saline in the same way. Patients were blinded to kind of injection.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Lack of benefits 1 year from preventive treatment or intolerance to their treatments.
  • 18 ≥ years old
  • Migraine without aura for more than 1 year, minimum of two or more migraine attacks per month.

Exclusion criteria

  • Patients with any chronic illness, medication overuse headache, a history of cranial and cervical surgery
  • Allergies to local anesthetics
  • Hemorrhagic diathesis
  • Alcohol or drug abuse

Treatment and study plan

Lidocaine injections

Procedure

Lidocaine injections. A mixture of 1 ml 2% lidocaine and 0.9% 1 ml saline was injected bilaterally to greater occipital nerve and supraorbital nerve in the blockade patients.

Saline injections

Procedure

Saline injections. Patients received 2 ml 0.9% saline in bilaterally to greater occipital nerve and supraorbital nerve

Primary outcomes

  1. Change of Frequency of Headache

    Time frame: Patients were followed up from baseline to 2 months after first injection.

    Number of headache days in a month. Scores from both months were averaged. Minimum=0 Maximum=30. Lower scores mean a better outcome.

  2. Change of Severity of Headache

    Time frame: Patients were followed up for 2 months from baseline after first injection.

    Mean visual analog scale (VAS) scores. Scores from both months were avareged. Minimum=0 Maximum=10. Lower scores mean a better outcome

Sponsors and collaborators

Lead sponsor

Dr. Lutfi Kirdar Kartal Training and Research Hospital

Other Gov

Registry information

Official study title

Greater Occipital and Supraorbital Nerve Blockade For The Preventive Treatment of Migraine

Important dates

Study start
2014
Primary completion
2015
Study completion
2016
First posted
Feb 15, 2018
Registry last updated
Mar 23, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.